MedLumics, company in which “la Caixa”, through Caixa Capital Risc and Ysisos Capital, invested in at the end of 2011 for the development of cardiac medical technology based on photonics, has announced the close of a financing round of 34,4 million euros. This financing round has been the largest round in the history of the medical technology industry in Spain, and one of the largest in Europe in the last year. The investment will allow to take its catheter AblaView out into the market. AblaView is the company’s main product and is aimed at the treatment of atrial fibrillation in the field of arrhythmias.

The round has been led by Edmond de Rothschild Investment Partners (EdRIP), and new investors include Seroba Life Sciences and Innogest Capitalademás of Ysios Capital Partners and Caixa Capital Risc. In consequence of said capital increase, the representative of Ysios Capital, Josep Lluís Sanfeliu, Olivier Litzka in representation of EdRIP, Claudio Rumazza of Innogest and James Greene of Seroba, will join the council together with the founder of the company Eduardo Margallo.

La fibrilación auricular es una de las principales dolencias en el ámbito de las arritmias. Se estima de 33,5 millones de personas sufrían arritmias de este tipo en 2010 y la prevalencia sigue creciendo por el envejecimiento de la población. AblaView supone un salto cualitativo en el tratamiento de esta enfermedad, ya que por primera vez los médicos dispondrán de un dispositivo que les permitirá en tiempo real y de forma directa ver el efecto de sus terapias.

Atrial fibrillation is on of the most common types of heart arrhythmia. An estimated 33.5 million people worldwide suffered from AF in 2010, and prevalence of the disease is expected to due to the ageing population. AblaView implies a qualitative leap in the treatment of this disease, as for the first time, doctors will have a device through which they will be able to watch the effects of their treatments in real time.

About MedLumics

Founded in 2009, MedLumics is a cardiology device Company specialising in minimally invasive optically guided medical devices. Their technological platform, Argia®, based on integrated optics, combines bot electrical and optical components on a small silicon chip. Argia® offers the possibility to create optical sensors that no larger than a grain of rice, but that are able to observe tissue in multiple directions, as well as handheld Optical Coherence Tomography systems to produce high quality images in real time. These products allow medical professionals to improve diagnosis and therapies throw optical evaluation (non-intrusive) of the tissue. For more information, visit: www.medlumics.com

About  Caixa Capital Risc

Caixa Capital Risc, the management arm of “la Caixa’s” venture capital, and invests in the first stages of innovative enterprises. Currently, Caixa Capital Risc manages near to 200 million euros and is a multisectoral investor that maintains focus on industries it considers to be emerging: technology, digital industries, manufacturing technology and life sciences.

Through its 8 investment vehicles, it has a portfolio of 175 companies.

About Ysios Capital

Ysios Capital is a venture capital management firm specializing in investments in life sciences, in particular, it invests in biomedicine, diagnosis and medical technology companies. Founded in 2008, Ysios capital manages 200 million euros under both of its funds. Its second fund, Ysios BioFund II Inniverte, has over 126,4 million euros and now has 7 participated companies. More information www.ysioscapital.com/